|
1
|
Sung H, Ferlay J, Siegel R, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN Estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Zhang TC, Chen H, Yin X, He Q, Man J, Yang
X and Lu M: Changing trends of disease burden of gastric cancer in
China from 1990 to 2019 and its predictions: Findings from Global
Burden of Disease Study. Chin J Cancer Res. 33:11–26. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang J, Xiu J, Farrell A, Battaglin F,
Arai H, Millstein J, Soni S, Zhang W, Shields A, Grothey A, et al:
Genomic landscapes to characterize mismatch-repair deficiency
(dMMR)/microsatellite instability-high (MSI-H) gastrointestinal
(GI) cancers stratified by tumor mutation burden (TMB). J Clin
Oncol. 41 (16 Suppl):S2618. 2023. View Article : Google Scholar
|
|
4
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Petrelli F, Antista M, Marra F, Cribiù F,
Rampulla V, Pietrantonio F, Dottorini L, Ghidini M, Luciani A,
Zaniboni A and Tomasello G: Adjuvant and neoadjuvant chemotherapy
for MSI early gastric cancer: A systematic review and
meta-analysis. Ther Adv Med Oncol. 16:1948–1957. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takei S, Kawazoe A and Shitara K: The new
era of immunotherapy in gastric cancer. Cancers (Basel).
14:10542022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang P and Gou H: Immunotherapy-based
therapy versus chemotherapy for the neoadjuvant treatment of
locally advanced dMMR/MSI-H gastric cancer. J Clin Oncol. 42
(16_suppl):e161212024. View Article : Google Scholar
|
|
8
|
Mou P, Ge Q, Sheng R, Zhu T, Liu Y and
Ding K: Research progress on the immune microenvironment and
immunotherapy in gastric cancer. Front Immunol. 14:12911172023.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marcus L, Lemery S, Keegan P and Pazdur R:
FDA approval summary: Pembrolizumab for the treatment of
microsatellite Instability-High solid tumors. Clin Cancer Res.
25:3753–3758. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu L, Li T, Deng S, Gao H, Jiang Y, Chen
Q, Chen H, Xiao Z, Shuai X and Su Z: Tertiary lymphoid structure
formation induced by LIGHT-engineered and photosensitive
nanoparticles-decorated bacteria enhances immune response against
colorectal cancer. Biomaterials. 314:1228462025. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fridman W, Sibéril S, Pupier G, Soussan S
and Sautès-Fridman C: Activation of B cells in Tertiary Lymphoid
Structures in cancer: Anti-tumor or anti-self? Semin Immunol.
65:1017032023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang FH, Zhang XT, Li YF, Tang L, Qu XJ,
Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, et al: Clinical guidelines
for the diagnosis and treatment of gastric cancer. Cancer Commun.
41:747–795. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim ST, Cristescu R, Bass AJ, Kim KM,
Odegaard JI, Kim K, Liu XQ, Sher X, Jun H, et al: Comprehensive
molecular characterization of clinical responses to PD-1 inhibition
in metastatic gastric cancer. Nat Med. 24:1449–1458. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiao X, Wei X, Li S, Liu C, Chen H, Gong
J, Li J, Zhang X, Wang X, et al: A genomic mutation signature
predicts the clinical outcomes of immunotherapy and characterizes
immunophenotypes in gastrointestinal cancer. NPJ Precis Oncol.
5:362021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Janjigian YY, Sanchez-Vega F, Jonsson P,
Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R,
Bouvier N, et al: Genetic predictors of response to systemic
therapy in esophagogastric cancer. Cancer Discov. 8:49–58. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a Histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
American Joint Committee on Cancer (AJCC),
. AJCC Cancer Staging Manual. 8th edition. Edge SB, Byrd DR,
Compton CC, et al: New York: Springer; 2017
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
André T, Tougeron D, Piessen G, de la
Fouchardière C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio
T, Desrame J, et al: Neoadjuvant nivolumab plus ipilimumab and
adjuvant nivolumab in localized deficient mismatch
Repair/Microsatellite Instability-high gastric or esophagogastric
junction adenocarcinoma: The GERCOR NEONIPIGA Phase II study. J
Clin Oncol. 41:255–265. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Obeid J, Hu Y, Erdag G, Leick K and
Slingluff C: The heterogeneity of tumor-infiltrating CD8+ T cells
in metastatic melanoma distorts their quantification: How to manage
heterogeneity? Melanoma Res. 27:211–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma W, Pham B and Li T: Cancer neoantigens
as potential targets for immunotherapy. Clin Exp Metastasis.
39:51–60. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hugo W, Zaretsky J, Sun L, Song C, Moreno
B, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G,
et al: Genomic and transcriptomic features of response to Anti-PD-1
therapy in metastatic melanoma. Cell. 165:35–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Fátima Aquino Moreira-Nunes C, De Souza
Almeida Titan Martins C, Feio D, Lima IK, Lamarão LM, de Souza CRT,
Costa IB, da Silva Maués JH, Soares PC, de Assumpção PP and Burbano
RMR: PD-L1 expression associated with Epstein-Barr virus status and
Patients' survival in a large cohort of gastric cancer patients in
northern brazil. Cancers (Basel). 13:31072021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shitara K, Van Cutsem E, Bang YJ, Fuchs C,
Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, et al:
Efficacy and safety of pembrolizumab or pembrolizumab plus
chemotherapy vs chemotherapy alone for patients With First-line,
advanced gastric cancer: The KEYNOTE-062 phase 3 randomized
clinical trial. JAMA Oncol. 6:1571–1580. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
O'Malley DM, Bariani GM, Cassier PA,
Marabelle A, Hansen AR, Acosta AJ, Miller WH Jr, Safra T, Italiano
A, Mileshkin L, et al: Pembrolizumab in microsatellite
instability-high/mismatch repair deficient (MSI-H/dMMR) and
non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158
study results. Gynecol Oncol. 193:130–135. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zeng D, Wu J, Luo H, Li Y, Xiao J, Peng J,
Ye Z, Zhou R, Yu Y, Wang G, et al: Tumor microenvironment
evaluation promotes precise checkpoint immunotherapy of advanced
gastric cancer. J Immunother Cancer. 9:e0024672021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li N and Li Y, Li J, Tang S, Gao H and Li
Y: Correlation of the abundance of MDSCs, Tregs, PD-1, and PD-L1
with the efficacy of chemotherapy and prognosis in gastric cancer.
Lab Med. 56:259–270. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim Y, Bae YJ, Kim JH, Kim H, Shin SJ,
Jung DH and Park H: Wnt/β-catenin pathway is a key signaling
pathway to trastuzumab resistance in gastric cancer cells. BMC
Cancer. 23:9222023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bernal M, Ruiz-Cabello F, Concha A,
Paschen A and Garrido F: Implication of the β2-microglobulin gene
in the generation of tumor escape phenotypes. Cancer Immunol
Immunother. 61:1359–1371. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moaaz M, Lotfy H, Elsherbini B, Motawea M
and Fadali G: TGF-β enhances the Anti-inflammatory effect of
Tumor-infiltrating CD33+11b+HLA-DR Myeloid-derived suppressor cells
in gastric cancer: A possible relation to MicroRNA-494. Asian Pac J
Cancer Prev. 21:3393–3403. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Niu Q, Liu J, Luo X, Su B and Yuan X:
Future of targeted therapy for gastrointestinal cancer: Claudin
18.2. Oncol Transl Med. 17:P102–P107. 2021. View Article : Google Scholar
|
|
35
|
Zhang D, Huang G, Liu J and Wei W:
Claudin18.2-targeted cancer theranostics. Am J Nucl Med Mol
Imaging. 13:64–69. 2023.PubMed/NCBI
|
|
36
|
Shitara K, Lordick F, Bang YJ, Enzinger P,
Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, et al:
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive,
HER2-negative, untreated, locally advanced unresectable or
metastatic gastric or gastro-oesophageal junction adenocarcinoma
(SPOTLIGHT): A multicentre, randomised, double-blind, phase 3
trial. Lancet. 401:1655–1668. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shah MA, Shitara K, Ajani JA, Bang YJ,
Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J,
Huang J, et al: Zolbetuximab plus CAPOX in CLDN18.2-positive
gastric or gastroesophageal junction adenocarcinoma: The
randomized, phase 3 GLOW trial. Nat Med. 29:2133–2141. 2023.
View Article : Google Scholar : PubMed/NCBI
|
